ADVENTRX logo
Company Products Clinical Trials Partners Investors Resources Contact
Resources

PUBLICATIONS
TECHNICAL LINKS
PUBLICATIONS

Anticancer References

  1. 5,10-Methylenetetrahydrofolic Acid with 5-Fluorouracil as Treatment for Advanced Breast Cancer in Patients who Failed Prior Treatment with Anthracyclines and Taxanes: a Phase 2 Study. J. Stewart1, G. Berman1, V.F. Semiglazov2, H. Gomez3, J.A. De La Cruz Vargas4, S. Falcon5, L.I. Akhmadullina6, A. Guerrero7, M. Varela8, C. Martin9; ADVENTRX Pharmaceuticals, Inc.1, San Diego, CA; Petrov Research Institute of Oncology2, St. Petersburg, Russian Federation.
    View poster presentation (pdf - 132 kb)
  2. Pharmacokinetic equivalence observed between an emulsion formuation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer, H. Requejo, L. Arboit, G. Arroyo, C. Blajman, L. Fein, P. Quintana, M. Chacon, M. Chantwell, D. Smith, J. Ellis, B. Demers, J. Stewart, J. Schupp, Instituto Medico Especializado Alexander Fleming, Bueno Aires, Argentina, April, 2008.
    View poster presentation (pdf - 118 kb)
  3. A novel emulsion formulation of docetaxel eliminates hypersensitivity reactions without impacting pharmacolkinets of antitumor activity, M. J. Cantwell, J. M. Robbins and A.X. Chen, American Association for Cancer Research (AACR) Annual Meeting 2007, Los Angeles, CA, October, 2007. View poster presentation (pdf - 616 kb)
  4. Antitumor activity and safety of a hybrid treatment regimen of 5,10-methylenetetrahydrofolate, 5-fluorouracil, and capecitabine in a colorectal tumor xenograft model, M. J. Cantwell and J. M. Robbins, American Association for Cancer Research (AACR) Annual Meeting 2007, Los Angeles, CA, April 14-18, 2007. View poster presentation (pdf - 335 kb)
  5. 5,10-Methylenetetrahydrofolate (CoFactor) enhances UFT antitumor activity against human colorectal HT-29 tumor xenografts in nude mice. M.J. Cantwell, J.M. Robbins. 7th International Conference of Asian Clinical Oncology Society (ACOS) & the 9th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Beijing, China, September 14-18, 2006. View poster presentation (pdf - 227 kb)
  6. Response to second line treatment following 5,10-methylenetetrahydrofolic acid (CoFactor) with 5-fluorouracil as first line treatment in metastatic colorectal cancer. T. Reid, C. P. Spears, M Subramanian, L. Pawl, G. Jankovic, S. Jelic, N. Milinic, L. Muzikravic, J. Stewart, J. M. Robbins. 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 28-July 1, 2006. View abstract (pdf - 24 kb)
  7. Pharmacokinetics of 5,10-methylenetetrahydrofolate administered as a 2-hour infusion. B Gustavsson, E. Odin, C. P. Spears, S. Radulovic, S. Susnjar, M Charney, M. J. Cantwell, J. M. Robbins. 8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 28-July 1, 2006. View abstract (pdf - 24 kb)
  8. 5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: phase II study results. T. Reid, C. P. Spears, R. Quadro, M. Subramanian, L. Pawl, G. Jankovic, S. Jelic, N. Milinic, L Muzikravic, J. M. Robbins. 42nd ASCO Annual Meeting, Atlanta, GA, June 3-6, 2006. View abstract (pdf - 16 kb)
  9. A novel emulsion formulation of vinorelbine attenuates venous toxicity while maintaining antitumor efficacy. M.J. Cantwell, J.M. Robbins, A. X. Chen. American Association for Cancer Research (AACR) 97th Annual Meeting 2006, Washington, DC. April 1-5, 2006. View poster presentation (pdf - 678 kb)
  10. 5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: a phase II study. T. Reid, C. P. Spears, R. Quadro, M. Subramanian, L. Pawl, G. Jankovic, S. Jelic, N. Milinic, L Muzikravic, JM Robbins. 2006 Gastrointestinal Cancers Symposium, San Francisco, CA. Jan 26-28, 2006. View abstract (pdf - 13 kb)
  11. 5,10-Methylenetetrahydrofolate enhances antitumor activity and reduces toxicity of 5-fluorouracil plus oxaliplatin combination therapy in a colorectal cancer xenograft model. M.J. Cantwell, J.M. Robbins. American Association for Cancer Research (AACR) special conference - Colorectal Cancer: Molecular Pathways and Therapies. Dana Point, CA. October 19-23, 2005. View poster presentation (pdf - 641 kb).
  12. A Simon two stage study of CoFactor (CO) with 5-fluorouracil (FU) as first line treatment in metastatic colorectal cancer (mCRC). C. Habita, T. Reid, C. P. Spears, R. Quadro, M. Subramanian, L. Pawl, G. Jankovic, S. Jelic, N. Milinic, L Muzikravic. 7th World Congress on Gastrointestinal Cancer, Barcelona, Spain. June 15-18, 2005. View abstract (pdf - 16 KB).
  13. A Simon 2 stage study of 5,10 methylenetetrahydrofolic acid (CO) with 5-fluorouracil (FU) as first line treatment in metastatic colorectal cancer (mCRC). T. Reid, C. P. Spears, R. Quadro, M. Subramanian, L. Pawl, G. Jankovic, S. Jelic, N. Milinic, L. Muzikravic, C. Habita. Proceedings of the American Society of Clinical Oncology (ASCO) 41st Annual Meeting, Orlando, FL, May 13-17 (2005). View abstract (pdf - 14 KB).
  14. 5,10-methylenetetrahydrofolate/5-fluorouracil combination therapy shows enhanced antitumor activity and lower systemic toxicity with a broad range of cytotoxic drugs: Mark J. Cantwell, Joan M. Robbins: 96th Annual Meeting of the American Association for Cancer Research (AACR), April 16-20 (2005), Anaheim, CA. View poster presentation (pdf - 790 KB).
  15. Pharmacodynamics of weekly intravenous methylene-tetrahydrofolate/5-fluorouracil on formic acid, RBC folate, and homocysteine levels in patients with metastatic colon cancer: C.P. Spears, R. Pineda, T. Reid, J. Robbins, C. Habita: 96th Annual Meeting of the American Association for Cancer Research (AACR), April 16-20 (2005), Anaheim, CA. View poster presentation (pdf - 745 KB).
  16. 5,10 Methylenetetrahydrofolate (CoFactor™) decreases 5-fluorouracil systemic toxicity without concomitant loss of antitumor activity: M.J. Cantwell, J.M. Robbins: 16th EORTIC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Conference, September 28-October 1 (2004), Geneva. View poster presentation.
  17. Antitumor activity of combination 5, 10-methylenetetrahydrofolate, 5-fluorouracil, and anti-vascular endothelial growth factor against human pancreatic AsPC-1 tumors in nude mice: M. J. Cantwell, J. M. Robbins: Pancreatic Cancer 2004 Advances and Challenges Conference, June 25-26 (2004). View poster presentation. (pdf - 578Kb)
  18. Antitumor activity of combination 5,10-methylenetetrahydrofolate, 5-fluorouracil, and anti-vascular endothelial growth factor against human colorectal HT-29 tumors in nude mice: M. J. Cantwell, C. P. Spears, J. M. Robbins: Proceedings of the American Society of Clinical Oncologists (ASCO) 40th Annual Meeting in New Orleans, June 5-8 (2004). View abstract. (pdf - 21Kb)
  19. Chemical Stability And Human Plasma Pharmacokinetics Of Reduced Folates: E. Odin, B. Sci, G. Carlsson, R. Frösing, B. Gustavsson, C.P. Spears, And P-A. Larsson: Cancer Investigation 16 (7) 447-455 (1998)
  20. Phase I-II Study Of Weekly 5-Fluorouracil And 5,10-Methylene-Tetrahydrofolate In Patients With Advanced Gastrointestinal And Breast Cancer: G. Carlsson, E. Odin, P-A. Larsson, R. Frösing, C.P. Spears, B., Gustavsson: The Cancer Journal, Vol 10 No. 5 September-October 1997.
  21. 5-Fluorouracil (5-FU) And 5,10-Methylene-Tetrahydrofolate (5,10CH2FH4) As Adjuvant Therapy In An Experimental Rodent Colon Carcinoma Model: G. Carlsson, L-O. Hafstrom, C.O. Spears, B. Gustavsson and P-A. Larsson: Anticancer Research 17: 3671-3674 (1997).
  22. Pharmacokinetics Of 5,10-Methylene-Tetrahydrofolate In Patients With Advanced Colorectal Cancer: Zarsson P-A., Carlsson G. and Gustavsson B.: Poster, European Congress of Clinical Oncology (ECCO), Paris 1995.
  23. Fluorouracil (FU) Plus 5,10-Methylene-Tetrahydrofolate ((D,L)-CH2FH4): Phase I-II Trial Of Weekly Bolus Therapy. Carlsson G., Frösing R., Larsson P-A., Spears C.P. and Gustavsson B.G.: Proc Am Soc Clin Oncol 14:469, 1995.
  24. Effects Of 5,10-Methylene-Tetrahydrofolate On Rat Tumour Growth And Biomodulation Of 5-Fluorouracil. Larsson P-A., Carlsson G., Gustavsson B., L-O. Hafstrom, A. Peterson, and C.P. Spears Regional Cancer Treatment (1995) 8:101-108.
  25. 5,10-Methylene-Tetrahydrofolate (CH2FH4) Effects On Rat Colon Tumor Growth And Biomodulation Of 5-Fluorouracil (FURA). Larsson P-A., Carlsson C., Spears CP. And Gustavsson B.: Poster at American Academy of Cancer Research, 85th Annual Meeting, San Francisco, USA 1994.
  26. 5-Fluorouracil And Methylene-Tetrahydrofolate As Adjuvant Therapy In An Experimental Colonic Adenocarcinoma In Rats. Carlsson G., Gustavsson B., Hafström L-O., Spears C.P.: 18th ICC:901-902, Stockholm, 1993.
  27. 5-Fluorouracil And Methylene-Tetrahydrofolate In Patients With Advanced Gastrointestinal And Breast Carcinoma. Carlsson G., Gustavsson B.G.: 18th ICC: 1017-1018, Stockholm, 1993.
  28. Pharmacologic (6R,S)-Tetrahydrofolate (FH4): Synergy With Fluorouracil (FURA) By Increased Thymidylate Synthase (TS) Inhibition, Decreased Methylene Units, And Promotion Of Unbalanced Growth. Spears C.P., Gustavsson B.G., Carlsson G., Frösing R., Proc Am Assoc Cancer Res 33:1581, 1992.
  29. Activation Of Leucovorin (CF) To Methylene-tetrahydrofolate (CH2FH4) For Improving Thymidylate Synthase (TS) Inhibition After 5-FU: Effects Of CF Dose, L-Serine, L-Glutamate, And Direct Methyl-Tetrahydrofolate (CH3FH4). Spears C.P., Gustavsson B.G., Carlsson G., Frösing R., Waugh W.J., Leichman C.G. and Muggia F.M.: Proc Am Soc Clin Oncol 8:69, 1989.
Antiviral References

  1. The Pyrophosphate Analogue Thiophosphonoformic Acid Confers a Favorable HIV Resistance Profile. S. Waninger, F. Amorsolo, J. Robbins, Keystone Symposia on HIV Pathogenesis, March 27 - April 1, 2008.
    View poster. (pdf - 4 Mb)
  2. Synergistic Antiretroviral Activity of Pyrophosphate Analogue ANX-201 Paired with Nucleoside Reverse Transcriptase Inhibitors In Vitro. S. Waninger, S. Ramos, J.M. Robbins, IAS Conference on HIV Pathogeneseis, Treatment and Prevention, Sydney, Austrailia, July 22-25, 2007. View poster. (pdf - 1.6 Mb)
  3. Combinations of Thiovir and Neuraminidase Inhibitors Exert Synergistic Antiviral Activitiy on Human, Equine and Avian Influenza In Vitro. S. Waninger, S. Ramos, J.M. Robbins, International Conference on Antiviral Research, Palm Springs, CA, April 29 - May 3, 2007. View poster. (pdf - 1.81 Mb)
  4. Thiovir exhibits broad-spectrum antiviral activity against human and avian influenza, human immunodeficiency, and herpes simplex viruses. S. Waninger, S. Ramos, J.M. Robbins, 14th International Symposium on HIV and Emerging Infectious Diseases, Toulon, France, June 21-23, 2006. (oral presentation).
  5. Synergistic Antiviral Activity and Additive Cytotoxicity of Thiovir Combined with Zidovudine. S. Waninger, S. Ramos, J. Robbins. Molecular Mechanisms of HIV Pathogenesis, Keystone, CO, March 27-April 2, 2006. View poster. (pdf - 364 Kb)
  6. Anti HIV-1 Activity of a Foscarnet Analogue, Synergy with Zidovudine and Analysis of Resistance Variants Selected In Vitro. S Waninger, S Ramos, J Robbins. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil. July 24-27 2005. View poster. (pdf - 939Kb)
  7. Pharmacokinetics of Potential Anti-AIDS Agents Thiofoscarnet and Foscarnet in the Cat. J.A. Straw, T.L. Loo, C.C. deVera, P.D. Nelson, W.A. Tompkins, and S.A. Bai. Journal of Acquired Immune Deficiency Syndromes 1992; 5(9): 936-42.
  8. Sodium thiophosphonoformate, a selective HIV RT inhibitor : facile synthesis and effects in HIV-infected cell culture. McKenna CE, Ye TG, Levy JN, et al. Ann NY Acad Sci 1990: 616: 569-72.


[ back to top ]

COMPANY | PRODUCTS | CLINICAL TRIALS | PARTNERS | INVESTORS | RESOURCES | CONTACT
HOME | CAREERS | SEARCH | SITE MAP | HELP | LEGAL
© Copyright 2008 ADVENTRX Pharmaceuticals
Search Careers Back to homepage